Ascendis Pharma Stock Drops After Ending Novo Partnership
Ascendis will develop TransCon obesity and cardiometabolic programs itself after ending its Novo collaboration and starting a $400M buyback.
/ 1642 items
#XY↓
GTBP’s Myeloma Headline Was Weaker Than It Sounded
FDA cleared a grant-dependent myeloma IND for GTB-5550. Cheap preferred, 100% warrants, and a tiny float explain the selloff.
Alignment Healthcare Slides After Conference Comments on Stars, Costs, and Ratings Uncertainty
Management cited Star-rating limits, HEI frustration, and a small cost rise.
GSK Buys Experimental Multiple Myeloma Drug from Chimagen
GSK will buy a Chimagen trispecific T-cell engager for multiple myeloma. Phase I trials start in 2027. The deal is worth up to $750 million.
BioVie Shares Fall After Mixed Phase 2 Long COVID Results for Bezisterim
Phase 2 ADDRESS-LC missed statistical significance overall. 21 of 22 measures favored bezisterim; benefits were strongest in severe-symptom subgroups.
H.C. Wainwright Upgrades Cardiff Oncology After Nerviano Settlement Clears Onvansertib Path
The catalyst: an out-of-court deal that keeps exclusive rights to onvansertib. Cash remains tight.